In 2019, the US FDA approved the administration of alpelisib in combination with fulvestrant for the treatment of metastatic breast cancer patients with hormone receptor-positive, HER2-negative breast cancer possessing PIK3CA-mutations, following disease progression on or after endocrine therapy [54]. Here, PIK3CA is linked to breast carcinoma.